-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Tango Therapeutics, Inc. quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2020 to 2024.
- Tango Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -$37.9M, a 35.2% decline year-over-year.
- Tango Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was -$111M, a 0.5% decline year-over-year.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly Data (USD)